Furmonertinib QD

Phase 2Small molecule

JJialei Wang

Furmonertinib QD is one of 3 small molecule programs targeting Disease Progression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Disease ProgressionRecruiting

Disease ProgressionPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Disease Progression

#DrugCompanyPhaseTrials

BRINEURA

BioMarin Pharmaceutical

Phase 2

1 2

Biltricide

Bayer

Preclinical

1 3

Furmonertinib QD

JJialei Wang

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Disease Progression

NCT06652048

Clinical

Trials by Indication[1]

Disease Progression1 trial

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Recruiting·JJialei Wang·Phase 2·NCT06652048·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Furmonertinib QD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Furmonertinib QD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Furmonertinib QD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jialei Wang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJialei Wang

Furmonertinib QD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Disease Progression1 trial

References

Drug Info

Quick Facts

Related News